Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CMPX
Strong SellCompass Therapeutics, Inc. · Healthcare · United States · $432M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary antibody-based therapeutics to treat cancer. The company utilizes its proprietary discovery platforms to target the human immune synapse, generating a pipeline of multi-specific candidates. Its competitive moat is anchored by its advanced antibody engineering capabilities and its promising lead oncology candidates in clinical trials.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0.8M | 0 | — | — | — | 22.4M | 197.6% |
| EPS | -0.37 | -0.33 | -0.36 | -0.42 | — | -0.39 | -0.49 | -0.54 | — |
| Shares | 126.3M | 127.7M | 137.8M | 178.3M | +41.2% | 180.1M | — | — | — |
| Debt | 2.9M | 1.7M | 6.6M | 9.8M | 49.6% | 9.6M | — | — | — |
| Equity | 181.6M | 148.5M | 125.2M | 196.8M | 2.7% | — | — | — | — |
| Op CF | -34.1M | -40.6M | -44.9M | -49.1M | — | -56.1M | — | — | — |
| Inv CF | -151.2M | 27.0M | 46.8M | -93.3M | — | — | — | — | — |
| Fin CF | 75.8M | 2.9M | 17.3M | 129.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CMPX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc.(you) | $432M | 5 | Strong Sell |
| VOGX | Vogenx, Inc. | $504M | 5 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $399M | 8 | Strong Sell |
| SCTX | Scribe Therapeutics Inc. | $460M | 2 | Strong Sell |
| OCGN | Ocugen, Inc. | $448M | 1 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 9 | Strong Sell |
| EYPT | EyePoint, Inc. | $376M | 2 | Strong Sell |
| LYEL | Lyell Immunopharma, Inc. | $356M | 8 | Strong Sell |
| CAPR | Capricor Therapeutics, Inc. | $558M | 3 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 10 | Strong Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%